Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Gilead Sciences, Inc shares valued at $249,550 were sold by Dickinson Andrew D on May 15 ’25. At $99.82 per share, Dickinson Andrew D sold 2,500 shares. The insider’s holdings dropped to 165,674 shares worth approximately $17.85 million following the completion of this transaction.
Also, ANDREW DICKINSON purchased 2,500 shares, netting a total of over 249,550 in proceeds.
Before that, Dickinson Andrew D had sold 2,500 shares from its account. In a trade valued at $266,000, the Chief Financial Officer traded Gilead Sciences, Inc shares for $106.40 each. Upon closing the transaction, the insider’s holdings decreased to 2,500 shares, worth approximately $18.12 million.
Analysts at Oppenheimer resumed the stock at ‘”an Outperform”‘ outlook in a report released in early March. As of February 18, 2025, Deutsche Bank has increased its “Hold” rating to a “Buy” for GILD. Earlier on February 13, 2025, DZ Bank upgraded its rating. Their new recommendation was “a Buy” for GILD stock which previously was a “a Hold”.
Analyzing GILD Stock Performance
During the last five days, there has been a surge of approximately 9.49%. Over the course of the year, Gilead Sciences, Inc shares have jumped approximately 16.62%. Shares of the company reached a 52-week high of $119.96 on 03/10/25 and a 52-week low of $88.57 on 01/10/25.
Support And Resistance Levels for Gilead Sciences, Inc (GILD)
According to the 24-hour chart, there is a support level at 107.15, which, if violated, would cause prices to drop to 106.58. In the upper region, resistance lies at 108.53. The next price resistance is at 109.34. RSI (Relative Strength Index) is 56.54 on the 14-day chart, showing neutral technical sentiment.
